Drug Profile

RC 1012

Alternative Names: RC-1012

Latest Information Update: 18 May 2023

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Guangdong Ruishun Biotech
Developer Anhui Provincial Hospital; WYZE Biotech
Class Antineoplastics; Cell therapies; Immunotherapies; T lymphocyte cell therapies
Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

04 May 2023 Phase-I/II clinical trials in Acute myeloid leukaemia (In adults, In the elderly, Prevention of relapse, Second-line therapy or greater) in China (Parenteral) (NCT05858814)
14 Jan 2021 Phase-I clinical trials in Acute myeloid leukaemia (Second-line therapy or greater) in China (Parenteral) (NCT05471323)
13 Jan 2021 Preclinical trials in Acute myeloid leukaemia in China (Parenteral), prior to January 2021

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com